1550. Engaging Black Women on Cabotegravir LA for PrEP by Optimizing Novel Implementation Strategies (EBONI) Study: Provider Perceptions of Appropriateness of Cabotegravir LA for PrEP for Cis-and-Trans Black Women

BACKGROUND: Black women comprise 55% and 46% of new HIV diagnoses among cisgender and transgender women in the United States, respectively.(1) Research has demonstrated the superiority of long-acting cabotegravir (CAB LA) for PrEP in reducing the risk of sexually acquired HIV-1 infection compared to...

Descripción completa

Detalles Bibliográficos
Autores principales: Richmond, Teriya, Dunn, Michael, Bernard, Marye, Urbaityte, Rimgaile, Sutton, Kenneth, Sutherland-Phillips, Denise, Dyson, Alftan, Merrill, Deanna, Chang, Samantha, Mack, Nicole, Haley, Amber, Brown, Kimberley, Evans, Tammeka
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2023
Materias:
Abstract
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10678956/
http://dx.doi.org/10.1093/ofid/ofad500.1385

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10678956/
http://dx.doi.org/10.1093/ofid/ofad500.1385

Ejemplares similares